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The progression of Alzheimer’s dementia is associated with neurovasculature impairment, which includes inflammation,
microthromboses, and reduced cerebral blood flow. Here, we investigate the effects of β amyloid peptides on the function of
platelets, the cells driving haemostasis. Amyloid peptide β1-42 (Aβ1-42), Aβ1-40, and Aβ25-35 were tested in static adhesion
experiments, and it was found that platelets preferentially adhere to Aβ1-42 compared to other Aβ peptides. In addition,
significant platelet spreading was observed over Aβ1-42, while Aβ1-40, Aβ25-35, and the scAβ1-42 control did not seem to
induce any platelet spreading, which suggested that only Aβ1-42 activates platelet signalling in our experimental conditions.
Aβ1-42 also induced significant platelet adhesion and thrombus formation in whole blood under venous flow condition, while
other Aβ peptides did not. The molecular mechanism of Aβ1-42 was investigated by flow cytometry, which revealed that this
peptide induces a significant activation of integrin αIIbβ3, but does not induce platelet degranulation (as measured by P-selectin
membrane translocation). Finally, Aβ1-42 treatment of human platelets led to detectable levels of protein kinase C (PKC)
activation and tyrosine phosphorylation, which are hallmarks of platelet signalling. Interestingly, the NADPH oxidase (NOX)
inhibitor VAS2870 completely abolished Aβ1-42-dependent platelet adhesion in static conditions, thrombus formation in
physiological flow conditions, integrin αIIbβ3 activation, and tyrosine- and PKC-dependent platelet signalling. In summary,
this study highlights the importance of NOXs in the activation of platelets in response to amyloid peptide β1-42. The
molecular mechanisms described in this manuscript may play an important role in the neurovascular impairment observed
in Alzheimer’s patients.
1. Introduction
Alzheimer’s disease (AD) is a multifactorial age-related neu-
rodegenerative disorder representing 60-80% of dementia
cases [1]. Prominent morphological hallmarks of the disease
include pathological accumulation of insoluble aggregates of
polymeric protein fragments known as β amyloid peptides
deposited in the brain parenchyma (amyloid plaques) and
within the cerebral vessel walls (cerebral amyloid angiopathy
(CAA)), formation of neurofibrillary tangles within neurons
(tau pathology), oxidative stress and chronic neurovascular
inflammation resulting in blood hypoperfusion, and dam-
ages to the blood brain barrier (BBB) [2]. The manifestation
of these pathological conditions eventually lead to neurovas-
cular dysfunction, neuronecrosis, cognitive decline, and ulti-
mately death [3].
Epidemiological data, postmortem pathological exami-
nation, and experimental studies on both human and animal
AD brains have revealed significant correlations and shared
pathophysiological mechanisms between Alzheimer’s and
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vascular diseases [4–9]. Common contributing causes
include conditions such as hypertension, diabetes mellitus,
hypercholesterolemia, apolipoprotein E (APOE) 4 polymor-
phism, and traumatic brain injury [10].
The potential role of platelets in Alzheimer’s disease has
been investigated in a number of studies. The initial work
of Rosenberg et al. in 1997 highlighted possible platelet acti-
vation in AD patients due to altered APP processing [11]. His
work was followed up by Sevush et al. in 1998 and by other
groups later on, and it was confirmed that there is an aberrant
and chronic preactivation of platelets that can eventually
contribute towards atherothrombosis, CAA, and progression
of AD [12]. Several studies showed a correlation between AD
and platelet abnormalities, including abnormal membrane
fluidity, increased β-secretase activity, and altered APP
metabolism [13]; α-degranulation, P-selectin surface expres-
sion, and integrin αIIbβ3 activation [14]; platelet adhesion
[15, 16]; formation of leukocyte-platelet complexes [12];
coagulation abnormalities [17–19]; and platelet adhesion
and accumulation at vascular β amyloid deposition sites,
where they were shown to modulate β amyloid complexation
into aggregates [20].
Several authors utilised both soluble and fibril forms of β
amyloid peptides as agonists and demonstrated that Aβ pep-
tides are able to promote platelet activation, adhesion, and
aggregation. For example, fibrillar Aβ1-40 was shown to
induce platelet aggregation by binding to scavenger receptors
CD36 and GP1bα and activating p38 MAPK/COX1 path-
ways. This induces the release of the potent aggregation ago-
nist thromboxane A2 (TxA2) [21]. Donner et al. more
recently showed that Aβ1-40 can bind to integrin αIIbβ3
and trigger the release of ADP and clusterin (a chaperone
protein), which promoted the formation of Aβ1-40 fibrils
[22]. In addition, the use of synthetic Aβ25-35, which retains
the biological and toxic properties of the full length Aβ1-40
and Aβ1-42, has been shown to activate the PAR1 thrombin
receptor and stimulate an intracellular signalling cascade
involving Ras/Raf, PI3K, P38MAPK, and cPLA2 and TxA2
formation and release [23].
NADPH oxidases (NOXs) are the only enzyme family
recognized for their sole primary function of generating reac-
tive oxygen species (ROS), and they have been proposed as
the main source of ROS in platelets during haemostasis
[24]. Recently, two types of NOXs have been identified in
human and mouse platelets (NOX1 and NOX2) [25], but a
comprehensive understanding of their activation signalling
pathways in response to β amyloid peptides remains elusive.
An interesting paper published by Walsh et al. demonstrated
that oligomeric and fibrillar forms of Aβ1-42 can act as a
ligand for the GPVI receptor and activate platelets [26]. Since
NOX1 has been shown to play a key role in signalling for the
GPVI receptor [25, 27], this may suggest that Aβ1-42 acts
through a NOX1-dependent activation of platelets.
Recently, we demonstrated that upon stimulation of
platelets by both monomeric or fibril forms of Aβ1-42, sig-
nificant intracellular superoxide anion formation can be
detected using a novel flow cytometry method using the
molecular probe dihydroethidium (DHE) [28]. Here, we fur-
ther investigate the effects of different Aβ (Aβ1-42, Aβ1-40,
Aβ25-35, and scrambled Aβ1-42 control) on platelet activa-
tion and adhesion in static and physiological flow conditions.
The use of pan-NOX inhibitor VAS2870 [28] allows the
assessment of the role of NOXs on platelet adhesion and acti-
vation. Our primary objective is to understand the mecha-
nism underlining β amyloid peptide-dependent regulation
of platelets, which can potentially improve our understand-
ing of AD and facilitate the development of pharmacological
tools to combat the progression of this disease.
2. Materials and Methods
2.1. Reagents. Dimethylsulfoxide (DMSO), indomethacin,
prostaglandin E1 (PGE1), bovine serum albumin (BSA),
sodium citrate solution (4% w/v), fibrinogen, thrombin from
human plasma, 4% w/v paraformaldehyde, TRITC-
conjugated phalloidin, 3,3′-dihexyloxacarbocyanine iodide
(DiOC6), VAS2870, D-(+)-glucose monohydrate, and 4-(2-
hydroxyethyl) piperazine-1-ethanesulfonic acid (HEPES)
were from Sigma-Aldrich (Poole, UK). Fibrillar collagen
was from Chrono-Log Corporation (Havertown, PA US).
The anti-phosphotyrosine antibody (4G10) was from
Upstate Biotechnology Inc. (Lake Placid, US). Anti-PKC
phosphor-substrate antibody was from Cell Signaling Tech-
nology (Danvers, US). Anti-pleckstrin antibody was from
Abcam (Cambridge, UK). FITC-PAC1 and PE-Cy5-CD62P
(P-selectin) antibodies were from Becton Dickinson,
(Wokingham, UK). Peroxidase-conjugated anti-IgG antibod-
ies were from Bio-Rad (Hercules, US). The chemiluminescent
substrate kit was from Merck Millipore (Burlington, US).
Amyloid peptides were synthesized by LifeTein (New Jersey,
US). The sequences of the peptides are as follows:
(i) Aβ1-40 (4.3 kDa): DAEFRHDSGYEVHHQKLVF
FAEDVGSNKGAIIGLMVGGVV
(ii) Aβ1-42 (4.5 kDa): DAEFRHDSGYEVHHQKLVF-
FAEDVGSNKGAII GLMVGGVVIA
(iii) Scrambled Aβ1-42: (4.5 kDa): DEFAKNIGHHDG-
VAVHMYKGRQVEFIGSIALVFEDVGSAGLV
(iv) Aβ23-35 (1.0 kDa): GSNKGAIIGLM
2.2. Preparation of Washed Platelets. Human whole blood
was obtained from healthy volunteers following Royal Devon
and Exeter NHS Foundation Trust Code of Ethics and
Research Conduct and under NRES South West – Central
Bristol committee approval (Rec n. 14/SW/1089). 20–30ml
of blood were drawn in the presence of the anticoagulant
sodium citrate (0.5% w/v). Platelet rich plasma (PRP) was
then isolated from whole blood by centrifugation at 200 × g
for 20mins. PRP was then subjected to a second centrifuga-
tion at 500 × g for 10mins in the presence of indomethacin
(10μM) and PGE1 (40 ng/ml). Platelets were resuspended
in modified Tyrode’s HEPES buffer (145mM NaCl, 2.9mM
KCl, 10mM HEPES, 1mM MgCl2, and pH7.3; 5mM D-
glucose was added before use).
2.3. Adhesion Assay. Round coverslips (22mm) were placed
in a clear flat-bottom 6-well plate and then coated overnight
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at 4°C with 10μM Aβ1-42, Aβ1-40, Aβ25-35, scrambled
Aβ1-42, or 5mg/ml BSA, all diluted in PBS. Excess solution
was then gently removed, and the coverslips were blocked
with 0.5% w/v BSA in PBS for 1 h at room temperature.
Coated dishes were then washed gently with PBS. Washed
platelets were resuspended at a density of 2 × 107 plate-
lets/ml. 0.5ml of washed platelets were incubated for 30mins
at 37°C. Nonadherent platelets were discarded, and the
adherent ones were gently washed with PBS and then fixed
with 4% w/v paraformaldehyde for 10mins at RT. 0.1% v/v
Triton X-100/PBS was added to permeabilize the platelets.
After 5mins, 0.1% Triton X-100/PBS was removed, and the
coated coverslips were washed with PBS and then blocked
with 5mg/ml BSA in PBS for 30mins. Fixed platelets were
then stained with 10μM TRITC-conjugated phalloidin for
1 hour at RT and then washed with PBS. Coverslips were
mounted onto microscope slides using Vectashield. Evalua-
tion of platelet adhesion and spreading was performed using
a Leica LED fluorescence microscope, and digital images
were acquired at 10x and 100x magnification objectives.
Platelet coverage and surface area were measured using Ima-
geJ (version 1.52e, Wayne Rasband, NIH).
2.4. Thrombus Formation Assay under Physiological Flow.
Human peripheral blood was anticoagulated with sodium
citrate 0.25% w/v. Platelets were fluorescently labelled by
incubation with 1μM 3,3′-dihexyloxacarbocyanine iodide
(DiOC6) for 10 minutes. ibidi Vena8 Fluoro+ microchips
(ibidi GmbH, Martinsried, Germany) were coated with
10μM Aβ peptides or 0.1mg/ml fibrillar collagen. Nonspe-
cific binding sites were saturated with 0.1% w/v BSA. Physi-
ological flow conditions (200–1000 sec−1) were applied
using an ExiGo pump (Cellix Ltd. Microfluidics Solutions,
Dublin, Ireland). Images of the thrombi formed after 10
minutes of flow were obtained with an EVOS Fl microscope
(Thermo Fisher Scientific, Waltham, MA, US). Platelet cov-
erage was measured using ImageJ (version 1.52e, Wayne Ras-
band, NIH).
2.5. Flow Cytometry. Platelets isolated as described above
were resuspended at 2 × 107 cells/ml density. After stimula-
tion in suspension as described (5–20μM Aβ1-42, Aβ1-40,
Aβ25-35, scrambled Aβ1-42, or 0.5 unit/ml thrombin) for
10 minutes at 37°C, platelets were incubated for a further
10 minutes with PAC1 and anti-P-selectin antibodies conju-
gated to FITC and PE-Cy5, respectively. 1 in 10 dilution in
Tyrode’s buffer was used to stop the immunolabelling of
the platelets. Surface fluorescence was assessed using a FAC-
SAria III flow cytometer (BD Biosciences, San Jose, USA).
2.6. Immunoblotting. Platelet samples (0.2ml, 1 × 109 plate-
lets/ml) were stimulated at 37°C under stirring conditions
(1,200 rpm) with Aβ1-42, Aβ1-40, and Aβ25-35 (including
1mM CaCl2) in a 490D aggregometer (Chrono-Log Corpo-
ration, Havertown, PA, US). Where indicated, the NOX
inhibitor VAS2870 (10μM) was preincubated for 10 minutes
before treatments with Aβ peptides. The reaction was
stopped after 3 minutes by the addition of a half volume of
3x SDS sample buffer (37.5mM Tris, pH8.3, 288mM
glycine, 6% SDS, 1.5% DTT, 30% glycerol, and 0.03% bromo-
phenol blue) followed by heating the samples at 95°C for 5
minutes. Platelet proteins were separated on SDS-PAGE gels,
transferred to a PVDF membrane, and analysed in immuno-
blotting using anti-phosphotyrosine antibody (4G10),
anti-phospho-PKC substrate antibody, and anti-pleckstrin
antibodies. Reactive proteins were visualized by ECL.
2.7. Statistical Analysis. Data were analysed by one-way
ANOVA with Bonferroni posttest using the statistical soft-
ware GraphPad Prism. Results were expressed as the mean
± standard error (SEM). Differences were considered signif-
icant at P value< 0.05.
3. Results
Initial experiments were carried out to examine the effect of
amyloidogenic peptides on human platelet adhesion in static
conditions by allowing platelet suspensions to rest on cover-
slips coated with scrambled Aβ1-42, Aβ1-42, Aβ1-40, and
Aβ25-35 for 30 minutes. Adhering platelets were then fixed,
permeabilized, and stained with TRITC-phalloidin. Phalloi-
din is a poisonous molecule extracted from the mushroom
Amanita phalloides that binds strongly to filaments of actin
(F-actin), which is a major component of the cell cytoskele-
ton [29]. In these experiments, phalloidin allows effective
visualization of adhered platelets. Figure 1(a) shows the high
number of adhered platelets to Aβ1-42. Adhesion to Aβ1-40,
or Aβ25-35 is higher than control scrambled Aβ1-42 pep-
tide, but this difference is not statistically significant. The
quantification of adhered platelets from 4 independent
experiments is shown in Figure 1(b). The statistical analysis
(one-way ANOVA with Bonferroni posttest) shows signifi-
cance (P < 0 05) for the increase in platelet adhesion to
Aβ1-42 compared to scrambled Aβ1-42.
In order to assess platelet spreading on Aβ peptides,
Figure 2(a) displays the morphological changes in adhering
platelets at a higher magnification (100x). Initial adhesion is
characterised by shape change from discoid into irregular
or round shape and filopodia formation, while complete
adhesion and signalling activation is associated with exten-
sive platelet spreading and formation of lamellipodia.
Aβ1-40 and Aβ25-35 induced only the morphological
changes of the early phase of platelet adhesion, with few fine
processes extending into different directions (filopodia). On
the other hand, platelets adhering to Aβ1-42 show full
spreading, with the formation of extensive lamellipodia and
a significant increase in surface area coverage. Figure 2(b)
quantifies the average surface area of the platelets confirming
the effectiveness of Aβ1-42 as a substrate for signalling acti-
vation and platelet spreading, while no platelet spreading is
observed for Aβ1-40 and Aβ25-35.
Since platelets demonstrated significant adhesion and
spreading on Aβ1-42, we next investigated the effects of the
NOX inhibitor VAS2870 on this substrate. Both platelet
adhesion and spreading were strongly impaired. In
Figure 3(a), we show the quantification of platelets adhering
to Aβ1-42 in the presence or absence of VAS2870. Although
the number of adhering platelets is not completely abated by
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Figure 1: β amyloid peptides in static conditions support platelet adhesion. Human platelet suspensions were plated on glass coverslips
coated with 10 μM scrambled Aβ1-42 (scAβ42), Aβ1-42, Aβ1-40, and Aβ25-35. The adhered platelets after 30 minutes shown in (a) were
fixed, permeabilized, and stained with TRITC-conjugated phalloidin and are representative images at 10x magnification. The
quantification of the adhered platelets evaluated as the mean number of platelets per optical field is shown in (b). Statistical significance
for 4 independent experiments was analysed by one-way ANOVA with Bonferroni posttest (∗P < 0 05), with bars representing standard
error of the mean (SEM).
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Figure 2: β amyloid peptides in static conditions support platelet spreading. Human platelet suspensions were plated on glass coverslips
coated with 10μM scrambled Aβ1-42 (scAβ42), Aβ1-42, Aβ1-40, and Aβ25-35. The adhered platelets shown in (a) were fixed,
permeabilized, and stained with TRITC-conjugated phalloidin and are representative images at 100x magnification. The quantification of
the mean surface area of the adhered platelets (μm2/plt) is shown in (b). Statistical significance for 4 independent experiments was
analysed by one-way ANOVA with Bonferroni posttest (∗P < 0 05), with bars representing standard error of the mean (SEM).
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VAS2870, there was a statistically significant decrease in the
number of adhering platelets in the presence of this inhibitor
(Figure 3(b)).
When observing adhering platelets at a higher magnifica-
tion (100x), VAS2870 appeared to significantly reduce the
platelet spreading and the resulting surface area per platelet
was lower than in the absence of the NOX inhibitor
(Figure 4(a)). Statistical analysis revealed statistical signifi-
cance of the effect of VAS2870 on platelet spreading
(Figure 4(b)).
Next, we tested whether Aβ peptides can stimulate plate-
let adhesion under physiological shear. We tested both arte-
rial (1,000 sec−1) and venous shear (200 sec−1) [30]. At
1,000 sec−1, the tensile strength of the binding of platelets to
Aβ peptides is not sufficient to guarantee effective adhesion
and thrombus formation (Figures 5(a) and 5(b)). At lower
shear rate corresponding to venous circulation (200 sec−1),
Aβ1-42 but not Aβ1-40, Aβ25-35, or scrambled Aβ1-42
induced convincing platelet adhesion and thrombus forma-
tion (Figures 5(c), 5(e) and 5(f)). Similarly to what was
observed in static conditions, the inhibition of NOX with
VAS2870 (10μM) inhibited platelet adhesion (and thrombus
formation) in response to Aβ1-42 (Figures 5(d) and 5(g)).
As the mechanisms leading to platelet adhesion to
Aβ1-42 remain unclear, but previous work suggest a role
for integrin αIIbβ3 on the adhesion to Aβ1-40 [22, 31], we
tested the activation of this integrin using the antibody
PAC1 by flow cytometry. These experiments suggested that
only Aβ1-42 (but not Aβ1-40, Aβ2535, or scrambled
Aβ1-42) induced a convincing activation of integrin αIIbβ3
(Figures 6(a)–6(g)). NOX inhibition with 10μM VAS2870
abolished Aβ1-42-induced αIIbβ3 activation (Figure 6(d)).
Interestingly, no significant translocation of P-selectin to
the surface of the platelets was observed, suggesting that Aβ
peptides (including Aβ1-42) cannot stimulate effective plate-
let degranulation on their own.
We next investigated the effect of Aβ1-42 on intracellular
platelet signalling using phosphospecific immunoblotting.
Both unstimulated and Aβ1-42-stimulated human platelets
were treated with either DMSO (control) or VAS2870. They
were then lysed, and the resulting protein extracts were sep-
arated by SDS-PAGE. Immunoblotting for phosphotyrosine
and phosphorylated PKC substrates is shown in Figure 7.
These antibodies are used to determine whether tyrosine
phosphorylation cascades and PKC are activated by Aβ1-42
treatment, but they do not allow the identification of the tar-
gets of the phosphorylation events and function as a qualita-
tive evidence of activation of the abovementioned signalling
pathways. In these experiments, pleckstrin is used simply as
a loading control. Tyrosine phosphorylation is one of the
key events that occur upon platelet activation, therefore
detecting tyrosine phosphorylation of platelet proteins pro-
vides a proof that Aβ1-42 induces platelet signalling activa-
tion. Figure 7(a) shows the phosphotyrosine profile of
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Figure 3: Effect of NOX inhibitor VAS2870 on platelet adhesion to Aβ1-42. Human platelet suspension was preincubated with NOX
inhibitor VAS2870 (10μM) for 30mins then plated on glass coverslips coated with 10 μM Aβ1-42 and 5mg/ml BSA in PBS. The numbers
of the adhered platelets fixed, permeabilized, and stained with TRITC-conjugated phalloidin are shown in (a), and representative images
at 10x magnification are displayed. The quantification of the adhered platelets evaluated as the mean number of the adhered platelets per
optical field is shown (b). Statistical significance for 4 independent experiments was analysed by one-way ANOVA with Bonferroni
posttest (∗P < 0 05), with bars representing standard error of the mean (SEM).
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resting and Aβ1-42-treated platelets in the absence or pres-
ence of VAS2870. Several bands are observed upon stimula-
tion with Aβ1-42 (compared to DMSO-treated controls),
which suggests activation of tyrosine kinase-dependent path-
ways and generation of tyrosine-phosphorylated protein sub-
strates. Very significantly, the pretreatment with VAS2870
leads to the abolishment of tyrosine phosphorylation in
response to Aβ1-42, which suggests that the activity of
NADPH oxidases is necessary for the signalling induced by
this peptide.
PKC is an essential protein kinase enzyme that is acti-
vated by diacylglycerol (DAG) and Ca2+ released from inter-
nal stores. The activation of PKC is a well-known intracellular
event induced by platelet activation, which is usually accom-
panied by phosphorylation of regulatory serine/threonine
residues in PKC substrate proteins [32–34]. In Figure 7(b),
several bands corresponding to different substrate proteins
for PKC appear more intensely upon Aβ1-42 stimulation,
suggesting that PKC is activated by this peptide. PKC activa-
tion is strongly associated to platelet activation and induction
of thrombus formation [34–36]. The abolishment of
phospho-PKC immunostaining by VAS2870 suggests that
NADPH oxidase activity is required for the Aβ1-42-depen-
dent platelet signalling leading to PKC activation.
4. Discussion
The differential ability of the tested β amyloid peptides to
induce platelet adhesive responses in static and flow condi-
tions is extremely interesting, but it remains difficult to
explain. Nonetheless, our observations are not isolated, as
Aβ1-42 has been identified as the most biologically active
of the amyloid peptides [37–39]. The biological activity of
Aβ1-42 is associated to a marked toxicity of this peptide
in several experimental systems [37–39]. One possible
explanation is the marked propensity of Aβ1-42 to form
fibrils compared to Aβ1-40 [40], which is due to the pro-
motion of intermolecular interactions between amyloid
monomers induced by the hydrophobic properties of the
extra amino acids of Aβ1-42 compared to Aβ1-40. Recent
studies have confirmed the enhanced propensity of Aβ1-
42 to form fibrils compared to other Aβ peptides [41, 42].
This draws an interesting parallel with the effect of collagen
on platelets. The activation of GPVI on platelets and induc-
tion of thrombus formation depends on the fibrillary struc-
ture of collagen (i.e., monomeric collagen does not induce
platelet activation) [43]. Therefore, similarly to collagen,
the β amyloid peptides may also need to be in a fibrillar
form to bind adjacent receptors and induce effective
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Figure 4: Effect of NOX inhibitor VAS2870 on platelet spreading on Aβ1-42. Human platelet suspension was preincubated with NOX
inhibitor VAS2870 (10 μM) for 30mins then plated on glass coverslips coated with 10μM Aβ1-42 and 5mg/ml BSA in PBS. The surface
area of the adhered platelets fixed, permeabilized, and stained with TRITC-conjugated phalloidin is shown in (a), and representative
images at 100x magnification are displayed. The quantification of the surface area of the adhered platelets (μm2/plt) is shown in (b).
Statistical significance for 4 independent experiments was analysed by one-way ANOVA with Bonferroni posttest (∗P < 0 05), with bars
representing standard error of the mean (SEM).
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Figure 5: Adhesion of platelets to amyloid peptides under physiological shear stress. Flow biochips (ibidi Vena8 Fluoro+) were coated with
0.1mg/ml fibrillary collagen or 10 μM scrambled Aβ1-42 (scAβ42), Aβ1-42, Aβ1-40, and Aβ25-35. Platelet adhesion was tested in human
whole blood at shear rates of 1,000 sec−1 and 200 sec−1. Where indicated, 10μM VAS2870 was added to the blood to inhibit NOXs.
Pictures shown here are representative of 3 independent experiments. Surface coverage analysis was performed using ImageJ and
statistically analysed by one-way ANOVA with Bonferroni posttest (∗P < 0 05).
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intracellular signalling in platelets. This seems to favour the
hypothesis that GPVI is the receptor for β amyloid peptides
on platelets, as this receptor preferentially binds substrates
in a fibrillary form, which allows the contemporaneous
interaction of the same fibril to different receptors (GPVI
and integrin α2β1 in the case of collagen) [44, 45].
Our static adhesion results are in partial disagreement
with older studies describing the ability of Aβ25-35 and
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Figure 6: Activation of integrin αIIbβ3 by Aβ1-42. Washed platelets were stimulated as indicated with Aβ1-42, Aβ1-40, Aβ25-35, or
scrambled Aβ1-42 or 0.5 units/ml thrombin for 10 minutes and then labelled with FITC-PAC1 (b-g) and PE-Cy5-P-selectin (h) for a
further 10 minutes. A side-scattering (SSC)/forward-scattering (FSC) dot plot is shown in (a) and suggests the high purity of the platelet
preparation. The histograms for the intensity of PAC1 staining in the different conditions are shown in (b-f) (representative of 3
independent experiments). Data analyses are shown in (g) and (h). Statistical analysis by one-way ANOVA with Bonferroni posttest is
shown in (g) and (h) (n = 3, ∗P < 0 05).
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Aβ1-40 to promote platelet adhesion [16, 22, 31, 46]. In real-
ity, in our experiments, Aβ1-40 and Aβ25-35 coating led to a
noticeable increase in platelet adhesion (from less than 200
platelets per optical field on scrambled peptides to around
400). Possibly because of the extent of the effect of Aβ1-42
(over 800 platelets per optical field), the effect of these two
peptides did not have statistically significant results. Analysis
of adhering platelets at a higher magnification revealed that
Aβ1-40 and Aβ25-35 did not induce extensive platelet
spreading, with most platelets adhering to these substrates
displaying a spherical morphology and modest filopodia for-
mation, which is indicative of partial activation. These data
are therefore suggesting some ability of Aβ25-35 and
Aβ1-40 to induce platelet adhesion, but a significantly higher
platelet adhesion to Aβ1-42, which is likely to induce more
extensive platelet intracellular signalling and full spreading
(as suggested by spreading data on Figure 3). The conditions
utilised for the resuspension of the peptides and the coating
of the surfaces in this and Canobbio et al.’s study of 2013
[16] are different, which is likely to affect the level of peptide
fibrillation and ability to bind platelets. Further investigation
of this discrepancy is necessary to fully understand how
platelet binding of β amyloid peptides is regulated. As plate-
let adhesion under static conditions recapitulates platelet
adhesion in the bloodstream, these data suggest the possibil-
ity that microthrombosis observed in the neurovasculature of
AD patients is due to platelet adhesion to Aβ1-42 accumulat-
ing in the perivascular space and migrating into the blood-
stream via endothelial cell transport [47].
We also tested Aβ peptides for their ability to induce
thrombus formation in whole blood under physiological
shear. In previous studies, it was shown that Aβ25-35 was
not able to induce thrombus formation on its own [35]. This
was confirmed in the present study. The ability of amyloid
peptides to potentiate platelet adhesion on collagen that we
showed in previous studies was not investigated in this man-
uscript because the Aβ1-42 peptide showed a remarkable
ability to induce platelet adhesion on its own. Although
Aβ1-42 has been shown to potentiate platelet adhesion to
collagen and other substrates previously [14, 48], here we
present the first evidence that this peptide alone is sufficient
to induce thrombus formation under flow.
Integrin αIIbβ3 has been suggested as the receptor on
platelets for Aβ1-40 [22, 31]. Therefore, we analysed whether
this integrin is activated in the presence of Aβ peptides.
Integrins are adhesion receptors characterised by two activa-
tion states (active and inactive), with only the active state able
to interact and bind its substrates. The signalling leading to
integrin activation is known as inside-out signalling, while
the signalling triggered by the engagement of the integrin
with its substrate is known as outside-in signalling [49]. With
the PAC1 antibody, we were able to assess the activation of
αIIbβ3, which is significant for Aβ1-42 (but not for
Aβ1-40, Aβ25-35, or scrambled Aβ1-42). This is a significant
finding suggesting profound differences in the biological
effect of Aβ peptides, with only Aβ1-42 inducing signalling
activation in platelets. This is in contrast with previous stud-
ies showing the signalling response induced by Aβ1-40 [22,
31] or Aβ25-35 [35]. This discrepancy remains difficult to
explain, but the differences in the experimental conditions
and the preparation of the peptide are a likely explanation.
In addition, our current study cannot categorically exclude
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Figure 7: Aβ42-induced signalling in platelets. (a, b) Unstimulated and Aβ42-stimulated (20 μM) human platelets were treated with 10μM
DMSO or VAS2870. Total proteins were separated by SDS-PAGE as described in the Materials and Methods, and protein phosphorylation
was analysed by immunoblotting with the indicated antibodies: (a) anti-p-Tyr and anti-pleckstrin antibody and (b) anti-PKC
phosphosubstrate and anti-pleckstrin antibody. The figure represents blots from three independent experiments.
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some level of platelet activation by other Aβ peptides (as
shown, e.g., in the static adhesion experiments where
Aβ1-40 and Aβ25-35 induce a moderate increase compared
to controls). Certainly, Aβ1-42 represents by far the most
active Aβ peptide in our hands.
One important question that remains unanswered relates
to the receptor responsible for the initial engagement of
Aβ1-42. Integrin αIIbβ3 is the most expressed and function-
ally crucial adhesion receptor in platelets [50]. Its activation
is the consequence of a signalling cascade known as inside-
out signalling, which requires receptor-dependent activation.
Therefore, although integrin αIIbβ3 is likely to participate in
platelet adhesion to Aβ peptides, an alternative receptor is
likely to exist. Different receptors have been suggested, includ-
ing protease-activated receptor 1 [23], GPVI [27], and CD36
[21]. Our current data do not help to resolve this impasse.
The intracellular signalling involved in platelet adhesion
and activation by β amyloid peptides has been studied by sev-
eral groups. For example, Sonkar et al. showed that exposure
to Aβ25-35 resulted in increased myosin light chain (MLC)
phosphorylation and RhoA-GTP levels. This led to the con-
clusion that Aβ25-35 induces cellular activation via RhoA-
dependent modulation of actin and cytoskeletal reorganisa-
tion [51]. Our previous investigations also showed that
Aβ25-35 promoted intracellular calcium increase by entry
from the extracellular environment, which led to dense gran-
ule and ADP release, and in turn to the activation of the
P2Y12 receptor, the small GTPase Rap1b, and both PI3K
and MAP kinase pathways [35]. In this study, we utilised
tyrosine phosphorylation and PKC-dependent phosphoryla-
tion tested by immunoblotting (Figures 7(a) and 7(b)) as
markers of platelet activation and to confirm that NOX
activity is crucial to trigger Aβ-dependent signalling in
platelets. No further detail on the signalling cascades trig-
gered by Aβ peptides can be drawn from this study. The
activation of tyrosine phosphorylation and PKC-dependent
protein phosphorylation cascades are central to platelet acti-
vation and common to most platelet agonists [52, 53]. We
have shown previously the modulation of PKC activity by
NOX inhibitors, possibly via dampening of GPVI receptor
signalling [25]. Other investigators highlighted the link
between NOX activation and PKC activity. In fact, this
appears to be a bidirectional interaction, not only with dif-
ferent PKC isozymes showing the ability to activate NOXs
(e.g., [54]) but also with NOX-dependent ROS leading to
oxidation and activation of PKC enzymes [55]. The data
from our current study could be explained by either direct
PKC stimulation or triggering of cell signalling leading to
PKC activation.
Interestingly, although the effect on αIIbβ3 by Aβ1-42
was very evident (i.e., similar to thrombin for 20μM
Aβ1-42), there was no apparent platelet degranulation, as
measured by P-selectin immunostaining. This implies that
differently to canonical agonists such as thrombin, collagen,
or thromboxane A2, Aβ1-42 induces integrin activation
without full platelet activation (i.e., partial stimulation).
This may explain the poor activity of Aβ1-42 as a platelet
agonist in some traditional assays, such as platelet aggrega-
tion [28].
In general, the variability in the peptides utilised (e.g.,
Aβ25-35, Aβ1-40, or Aβ1-42) and the focus of different stud-
ies on different receptors and signalling pathways led to
apparently contradicting results. For example, an intriguing
study reported the reduction of Aβ peptide-dependent plate-
let activation by fibrinogen [56]. Although the underlying
mechanisms remain difficult to explain, this observation
may be correlated to our data on Aβ peptide-dependent acti-
vation of integrin αIIbβ3 (which is the main fibrinogen
receptor on platelets). The use by authors of the above study
of a different Aβ peptide for their stimulations (i.e., Aβ25-35)
makes any comparison of our and their studies difficult. Fur-
ther studies are required to resolve these contradictions.
This study highlights the importance of NADPH oxidase
activation and platelet oxidative responses in the prothrom-
botic responses induced by Aβ1-42, which is the β amyloid
peptide accumulating in the brain of Alzheimer’s and cere-
bral amyloid angiopathy (CAA) patients. In addition to giv-
ing us some direction in the elucidation of the molecular
mechanisms underlying platelet activation by β amyloid pep-
tides, these data suggest a potential therapeutic opportunity
aiming at limiting the vascular component of Alzheimer’s
disease by targeting NADPH oxidase activity.
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